Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Business

Posted By Uma Rajagopal

Posted on December 5, 2024

GSK expands deal with China’s Zhifei to explore RSV vaccine collaboration

(Reuters) -GSK said on Thursday it had expanded its agreement with China’s largest vaccine company Zhifei to explore a potential collaboration on the British drugmaker’s respiratory syncytial virus (RSV) vaccine, Arexvy.

Last year, London-listed GSK said Zhifei would pay it 2.5 billion pounds ($3.18 billion) for the exclusive rights to distribute GSK’s shingles vaccine, Shingrix, in the world’s No.2 pharmaceuticals market.

GSK said on Thursday it has revised the terms on which Zhifei will commercialise Shingrix in China to 2034.

Under the revised agreement, Zhifei has also agreed to engage exclusively with GSK to explore a potential collaboration on Arexvy, with an initial term of 10 years.

The companies expect that Zhifei will purchase volumes of Shingrix, phased over time, with a potential total value to GSK of 2.3 billion pounds ($2.93 billion) over the six-year period from 2024 to 2029.

($1 = 0.7860 pounds)

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D’Souza and Rashmi Aich)

Recommended for you

  • Alaamry Global Capital’s Annual Letter: Saudi Investor Khalid Alaamry on Strategic Thinking for International Markets.

  • Enhancing Guest Loyalty in Hospitality: The Impact of Personalized Services on Customer Satisfaction

  • Building Brand Equity in Luxury Goods: The Role of Heritage and Craftsmanship